Lilly to Invest in QurCan Under Genetic Medicines Deal (LLY)
7 Articles
7 Articles
Financial Post
India ShortsQurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases
Multi-program collaboration leveraging QurCan’s TERP™ polymer-lipid nanoparticle delivery platform Lilly to make a strategic investment in QurCan TORONTO — QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with E…
Collaboration across various programs leverages QurCan’s TERP™ platform for polymer-lipid nanoparticle delivery Lilly Makes Strategic Investment in QurCan TORONTO–(BUSINESS WIRE)– QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, PLNP (polymer-lipid nanoparticle) delivery of genetic medicines via its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaborat…
In collaboration with the daily newspaper l'Adige we receive and publish the link of the following news. Opinion and thanks the publisher for the multimedia partnership. /// QurCan Therapeutics makes a strategic agreement of research and collaboration with Lilly to carry out the nucleic acid therapies for the diseases of the central and peripheral nervous system. Link to the [...]
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
